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Background: To ensure the safety of plasma derivatives, screening for human parvovirus B19V genomic DNA in
donated plasma using a pooling strategy is performed in some countries. We investigated the prevalence of B19V
DNA and anti-B19V antibodies in Chinese plasma pools, plasma derivatives and plasma donations to evaluate the
risk posed by B19V.
Methods: Using a Q-PCR assay developed in-house, we tested for B19V genomic DNA in 142 plasma pools
collected between January 2009 and June 2011 from two Chinese blood products manufacturers. Plasma
derivatives collected between 1993–1995 (10 batches of albumin, 155 batches of intravenous immunoglobulin, IVIG)
and 2009–2011 (50 batches of albumin, 54 batches of IVIG, 35 batches of factor VIII, 7 batches of fibrinogen, and 17
batches of prothrombin complex concentrate, PCC) were also tested for B19V contamination. In addition, B19V
genome prevalence in minipools(including 90 individual donations) of 49680 individual plasma samples collected
between August 2011 and March 2012 by a single Chinese manufacturer was investigated. IgM/IgG was also
investigated in plasma pools/derivatives and in minipools with B19V-DNA titers above 1x104 and 1x106 geq/mL
using B19 ELISA IgM/IgG assay(Virion-Serion, Würzburg, Germany), respectively.
Results: B19V-DNA was detected in 54.2% of plasma pools from two Chinese blood product manufacturers; among
recently produced blood products, B19V was detected in 21/54 IVIG samples, 19/35 factor VIII samples, 6/7
fibrinogen samples, and 12/17 PCC samples, but not in albumin samples. The levels of B19V-DNA in these samples
varied from 102-107 geq/mL. In samples with >104 geq/mL genome DNA, B19V-specific IgG was also found in all
corresponding plasma pools and IVIG, whereas none was detected in the majority of other plasma derivatives.
Screening of plasma donations indicated that most minipools were contaminated with B19V-DNA (102-108 geq/mL)
and one donation had 1.09 × 1010 geq/mL B19V genomic DNA along with a non-classical IgG/IgM profile.
Conclusions: Despite the implementation of some inactivation/removal methods designed to prevent viral
contamination, B19V DNA was detectable in Chinese plasma pools and plasma derivatives. Thus, the introduction of
B19V screening and discard donation with high viramic concentration for Chinese plasma donors would be
desirable.Background
Human parvovirus B19V is a small icosahedral, non-
enveloped single-stranded DNA viral pathogen that can
cause a variety of diseases, including erythema infectio-
sum (fifth disease), arthritis, transient aplastic crisis,* Correspondence: zhangyan@ronsen.com; lwpzhr@sina.com
1Institute of Blood Transfusion, Chinese Academy of Medical Sciences and
Peking Union Medical College, Hua Cai Road 26 Hao, Dong San Huan Road
Er Duan, Chengdu, Sichuang 610052, China
2Cheng Du Rongsheng Pharmaceuticals Co. LTD, Hua Cai Road 26 Hao,
Dong San Huan Road Er Duan, Chengdu, Sichuang 610052, China
Full list of author information is available at the end of the article
© 2012 Zhang et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the orchronic anemia (in immunocompromised patients),
hydrops fetalis, and fetal death[1-4]. The main route of
B19V transmission is via the respiratory route, although
it can also be transmitted vertically and via blood transfu-
sion and organ transplantation[5]. B19V infection usually
happens during childhood; however, 40–60% of adults
are still susceptible to primary infection [6,7]. Depending
on assay sensitivity and epidemic incidence, the preva-
lence of B19V DNA in blood donors can be up to 1%,
with virus titers reaching 1 × 1014 geq/mL during early
acute infection, although affected individuals are often
asymptomatic. This level of prevalence is sufficient toLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[8,9], and, eventually, plasma derivatives that are usually
prepared from pools of several thousand donations. One
study demonstrated that, overall, 85% (60–100% depend-
ing on manufacturer) of plasma pools, 25% of albumin
samples, 100% of factor VIII, 20% of IVIG, and 75% of
intramuscular immunoglobulin preparations contained
B19V DNA [10]. Viral load in those samples ranged from
1× 102 to 1 × 106 geq/mL. Another study reported a high
prevalence (over 60%) of B19V DNA in factor IX, factor
VIII, PCCs, and plasma pools with viral loads of 1 × 102
to 1 × 108 geq/mL [11].
The small size (20–25 nm in diameter) and non-
enveloped nature of B19V render it difficult to remove by
filtration methods and very resistant to many virus in-
activation procedures used in the production of plasma
derivatives, including solvent/detergent (S/D) and heat
treatment. The transmission of B19V through the admin-
istration of S/D-treated [12] and certain dry heat-treated
blood products has already been documented [13-15].
B19V can also be transmitted by blood component
[16,17], while one study indicated only high concentra-
tion containing component can cause infection[18].
Transmission of B19V by blood and blood products and
its resistance to common viral inactivation/removal
methods raises the importance of detecting B19V prior
to blood transfusion. The FDA has proposed a limit of
104 geq/mL for manufacturing pools destined for all
plasma derivatives to reduce the potential risk of trans-
mission [19,20]. Similarly, European Pharmacopoeia has
imposed a limit of 104 IU/mL for levels of B19V in anti-
D immunoglobulins and pooled virus inactivated plasma.
Many studies have demonstrated the presence of B19V
DNA in plasma pools and plasma-derived products
[11,21-24]; however, the prevalence of B19V DNA in
Chinese blood products and plasma pools has not been
extensively investigated. In this study, we aimed to deter-
mine the frequency and level of B19V DNA contamin-
ation in plasma pools collected during 2009–2011, and
in plasma-derived products produced during two peri-
ods,1993–1995 (albumin, IVIG) and 2009–2011(albu-
min, IVIG, factor VIII, Fibrinogen), under license in
China. Since no B19V Nucleic Acid Testing (NAT) regi-
men has previously been proposed for Chinese blood
products manufacturers, the results of the present study
will hopefully provide a significant advance in this area
and have a positive impact on policy development with
regard to blood safety in China.
Materials and methods
Samples
We tested 142 industrial pools used for fractionation
into plasma derivatives between January 2009 and June
2011 from two regional different Chinese blood productsmanufacturers. The study also included 10 batches of
albumin and 155 batches of IVIG prepared between
1993 and 1995 and stored in our lab, and 50 batches
of albumin, 54 batches of IVIG, 35 batches of factor
VIII, 7 batches of fibrinogen, and 17 batches of PCC
prepared between 2009 and 2011. We also investigated
B19V genome DNA contamination in minipools of
49680 individual plasma samples collected between Au-
gust 2011 and March 2012 by one of those two Chinese
manufacturers. A protocol to investigate B19V DNA in
plasmapheresis donors was developed. Briefly, aliquots
of individual plasma samples (10 μL) from 90 human
donations were pooled, and orerall 552 mini-pools were
obtained. DNA was extracted from a 200 μL mini-pool
as described above; 5 μL of extracted DNA was used for
PCR amplification and quantitation of B19V DNA.
When a test pool exceeded the threshold of 106 geq mL
B19V DNA, the pool was broken down via subpools of
10 donations, and all individual donations in a reactive
subpool were tested to identify the highly viraemic
donation.B19V DNA extraction and quantitation by Q-PCR
A volume of 200 μL pooled source plasma or plasma
derivative was subjected to nucleic acid extraction
using the TIANamp virus DNA/RNA kit (TIANGEN),
according to the manufacturer’s instructions. All DNA
extracts were stored at -80°C prior to PCR analysis.
IUs were adjusted to genome equivalent (geq) using
plasmid pYT-103, which contains the sequence of the
B19V Genotype 1 genome. The conversion ratio from
geq to IU is 1.02. Before quantitation of B19V genome
of the DNA extracts, the specificity of the primers and
the sensitivity of the detection system were tested as
previously described[25]. The DNA extracted from the
WHO International standards (NIBSC 09/110; 106 IU
of B19V DNA/mL) were used to determine the conver-
sion ratio from geq to IU and to validate the specificity
of the primers. Meanwhile, a serial dilution of plasmid
pYT-103 which contains sequence of B19V Genotype 1
genome was used to investigate the sensitivity of the de-
tection system. Briefly, a serial dilution (10×) of pYT-103
from 5 to 5 × 107 geq per reaction(20 μl) for NAT based
assays were tested for the lowest detection limit. If a
signal of the lowest standard was detected at more than
40 cycles, the result was interpreted as invalid and
repeated the experiment. This warrant the sensitivity of
the experiment is much lower than 125 geq/mL and guar-
antees our data to fulfil the criteria. The sequence of the
forward primer is 50-TGCAGATGCCCTCCACCCA-30
and the sequence of reverse primer is 50-GCTGCTTTCA
CTGAGTTCTTC-30 which are located in the NS1
gene (NS1-PCR) and can amplify all three B19V
Table 1 The prevalence and levels of B19V DNA in





B19V DNA (geqmL) among
positive lots
≥ 104 ≥ 103 ≥ 102 Log geq
± SEM
Company A 24/80 (30%) 7 9 8 3.96 ± 1.67
Company B 53/62 (85.5%) 26 26 1 4.79 ± 1.77
Total 77/142 (54.2%) 33 35 9 4.95 ± 1.67
SEM standard error of log geomean.
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PCR (Q-PCR) assays were performed on an ABI Prism
7900 Sequence Detection System platform (Applied Bio-
systems, Foster City, CA) using a SYBR Green I (Mo-
lecular Probes, Eugene, OR) PCR mix. Briefly, the 20 μL
reaction mix consisted of 10 μL FastStart Universal
SYBR Green Master (Rox) (Roche Diagnostics, Indian-
apolis, IN, USA), 12.5 pmol of each primer, and 5 μL
extract DNA as a template. Hot-start amplification was
performed under the following conditions: 1 cycle of
95°C for 10 min; 45 cycles of 95°C for 15 s, 60°C for
30 s, and 72°C for 30 s; and a final cycle of 95°C for
15 s, 60°C for 15 s, and then gradually increased to
95°C in 30 min at a ramp rate of 2%. Detailed Q-PCR
procedures have been previously described [26]. Q-PCR
detected B19V DNA positive samples were confirmed
by nested PCR (nPCR) using the conserved primers
located in the NS1 region described previously[25].
B19V serologic assays
Testing for B19V-specific antibodies was performed
with a commercial assay kit (parvovirus B19V immuno-
globulin IgG or IgM enzyme immunoassay, Virion-Serion,
Würzburg, Germany) according to the manufacturer’s
recommendations. The detecting kit of IgG was against
B19V recombinant VP1 and the detecting kit of IgM was
against recombinant VP1/VP2. All the plasma products
and plasma pools with B19V genomic DNA titers higher
than 104 geq mL and resolved viraemic individual dona-
tions were tested. Samples were initially tested a single
time; if results were equivocal, the assay was repeated and
an unambiguous result was taken as the final value for the
specimen.
Results
Q-PCR sensitivity and specificty
To determine the sensitivity of the Q-PCR assay, 10 indi-
vidual plasma samples with no detectable anti-B19V spe-
cific IgM or IgG were selected as negative controls. When
tested by Q-PCR, the 10 negative samples demonstrated no
specific amplification after a total of 50 PCR cycles. The de-
tection limit of the B19V DNA Q-PCR assay was deter-
mined by performing 10-fold serial dilutions of plasmid
PYT-103 into plasma negative for B19V genomic DNA.
The highest dilution at which all four replicates were posi-
tive was taken as the end-point. The detection limit was
5 geq of B19V DNA in each PCR reaction, which is equiva-
lent to 125 geq/mL per sample. As our previously study
indicated[25], our in-house Q-PCR was efficient in amplify-
ing all three B19V genotype. For screening, reactive plasma
pool samples were re-tested in duplicate and confirmed by
nested PCR (data not shown). If a signal of the lowest
standard was detected at more than 40 cycles, the result
was interpreted as invalid and repeated the experiment.Prevalence of B19V DNA and antibody in plasma pools
To investigate the prevalence and levels of B19V DNA
in plasma pools, NAT was performed using pools des-
tined for plasma derivatives made by two manufacturers
of Chinese blood products in the period 2009–2011. As
shown in Table 1, 24 of 80 (30%) plasma pools from
company A were positive for B19V DNA. Of these 24
pools, seven contained >104, and seventeen < 104 geq/
mL. However, in the same period, plasma pools from
company B had a much higher prevalence of B19V gen-
ome DNA; 53 of 62 (85.5%) plasma pools were positive
for B19V DNA, among which 26 contained more than
104 geq/mL and 27 less than 104 geq/mL. The quantity
of B19V DNA varied from 102 to 3.07 × 108 geq/mL.
Plasma pools with a viral load higher than 104 geq/mL
are shown in Table 2. The anti-B19V IgG and IgM titers
were also determined in plasma pools that contained
levels of B19V DNA higher than 104 geq/mL (Table 2).
All plasma pools were positive for IgG, with titers in the
range of 6–52.5 IU/mL. Twenty one of 33 (65.6%) batches
of plasma pools contained IgM, and the titer varied from
5.4–50 IU/mL. There was no correlation between levels
of B19V DNA content and the titer of IgG/IgM.
B19V DNA and antibodies in plasmapheresis donors
A total of 49680 individual plasma samples collected from
company A between August 2011 and March 2012 were
pooled into 552 pools(each pool contained 90 individual
donation) and tested for B19V DNA contamination. Of
these, one pool contained B19V DNA at a level higher
than 108 geq/mL; 24, 64, 342 and 105 contained B19V
DNA at levels between 1–10× 105 geq/mL, 1–10× 104]
geq/mL, 1–10× 103 geq/mL, and 1–10× 102 geq/mL, re-
spectively; and 16 pools had no detectable B19V DNA.
Overall, 97% (536 of 552) mini-pools were contaminated
with B19V DNA, however, most of the pools contained
low B19V genome DNA. The pool containing >106 geq/mL
was resolved to identify an individual highly viraemic
donation with 1.09 × 1010 geq/mL B19V genomic DNA.
IgM and IgG were negative at the index time. The
results of retrospective and follow-up tests are shown in
Table 3. B19V DNA titers were lower at subsequent
Table 2 B19V DNA and antibodies in plasma pools with B19V genome titers >104 geq/mL
Sample source Company/Lot number Viral load (geq/mL) IgG (IU/mL) IgM (IU/mL)
Company A A-1 1.17 × 108 15.2 Ne
A-2 9.43 × 107 15.5 6.8
A-3 2.13 × 106 17.5 Ne
A-4 1.59 × 106 12.9 Ne
A-5 1.63 × 105 21 12.2
A-6 9.42 × 104 17 16.5
A-7 1.42 × 104 17.9 9.3
Company B B-1 3.07 × 108 14.5 50
B-2 2.63 × 108 20 21.5
B-3 1.83 × 108 22 Ne
B-4 1.44 × 108 30 Ne
B-5 1.28 × 108 24.8 Ne
B-6 9.88 × 107 10.2 18.8
B-7 9.22 × 107 16 5.4
B-8 2.79 × 107 21 31.8
B-9 1.29 × 107 9.3 8.2
B-10 8.78 × 106 39 Ne
B-11 2.1 × 106 20.5 10.5
B-12 1.02 × 106 45 42
B-13 8.41 × 105 11.7 6.4
B-14 5.9 × 105 11.8 13
B-15 5.23 × 105 12.5 12.5
B-16 3.59 × 105 18.8 25
B-17 2.72 × 105 6 Ne
B-18 8.22 × 104 7.5 14.8
B-19 5.16 × 104 24.5 25.5
B-20 3.86 × 104 52.5 Ne
B-21 1.99 × 104 28 6
B-22 1.86 × 104 23.5 Ne
B-23 1.55 × 104 14.9 21
B-24 1.49 × 104 21.6 14.1
B-25 1.34 × 104 24.8 Ne
B-26 1.07 × 104 11.4 Ne
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2.07× 104 geq/mL 10 weeks after the index time. Surpris-
ingly, the retrospective sample, collected two weeks before
the index time, was IgG positive with 17.4 IU/mL and had
a B19V DNA titer of 2.29× 106 geq/mL. IgM and IgG be-
came detectable two weeks after the index time. Although
samples from the following four donations remained
positive for both antibodies, the IgG level continued to
increase, whereas the IgM level decreased.
B19V DNA in plasma derivatives
Table 4 summarizes the B19V DNA content in plasma
products. Overall, 71/328 (21.6%) of these products were
contaminated with B19V DNA. In 3 of 10 batches ofalbumin produced during 1993 to 1995, B19V DNA
was detectable; however, the products contained
<104 geq/mL. B19V DNA was not detected in any of
the 50 batches of albumin produced during the period
2009–2011. For IVIG, 6.5% (10 of 155) of tested
batches produced from 1993 to 1995 contained B19V
DNA at concentrations up to 7.75× 106 geq/mL, eight
batches were highly contaminated (≥104 geq/mL) and
two contained < 104 geq/mL. The ratio of B19V DNA
positive IVIG produced during 2009–2011 was 38.9%
(21 of 54 batches), which was significantly higher than
that produced during 1993 to 1995. However, 18 posi-
tive batches contained B19V DNA at <104 geq/mL, and
only three batches were highly contaminated (≥104 geq/
Table 3 B19V DNA and anti-B19V antibodies in
retrospective and follow-up specimens from an individual
highly viraemic donation
Sampling date Viral load (geq/mL) IgG (IU/mL) IgM (IU/mL)
2011.11.25 2.29 × 106 17.4 Ne
2011.12.08 1.09× 1010 Ne Ne
2011.12.22 6.26 × 106 34.2 24.5
2012.1.5 1.68 × 105 69 12
2012.1.19 1.60 × 105 87 8
2012.2.2 5.76 × 104 88.5 7.3
2012.2.16 2.07 × 104 75 6
Ne Negative. Bold text indicates the index sample.
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tested positive for B19V DNA with levels of up to
1.87× 105 geq/mL, among which six batches were highly
contaminated (≥104 geq/mL) and 13 batches moderately
contaminated (<104 geq/mL). Among seven batches of fi-
brinogen produced between 2009 and 2011, six (85.7%)
were contaminated with B19V genomic DNA, three were
highly contaminated (≥104 geq/mL), and three contained
less than 104 geq/mL. For PCC produced in the same
period, 53% (12 of 17 batches) were contaminated, with
four and eight containing B19V DNA levels higher and
lower, respectively, than 104 geq/mL. B19V DNA and anti-
bodies in plasma derivatives with genome titers >104 geq/
mL are shown in Table 5. Among these plasma deriva-
tives, all IVIG were positive for IgG, with titers in the
range of 7.5-144 IU/mL, all the other derivatives contained
no IgG except two batches Fibrinogen contained low level
IgG. For IgM, most of the derivatives were negative, ex-
cept 3 of 4 batches of PCC and 2 of 3 batches of Fibrino-
gen contained low level. Besides, two batches of IVIG
were positive for IgM with one in low level and one in
high level. There was no association of levels of B19V
DNA content and the titer of IgM/IgG.
Discussion
Blood products have been widely used for the prevention







1993–1995 albumin 3/10 (30%) 0
IVIG 10/155 (6.5%) 8
2009–2011 albumin 0/50 (0) 0
IVIG 21/54 (38.9%) 3
factor VIII 19/35 (54.3%) 6
Fibrinogen 6/7 (85.7%) 3
PCC 12/17 (53.0%) 4
Total 71/328 (21.6%) 24
SEM standard error of log geomean.diseases; however, the contamination of these products
with viruses also poses a great threat to patients. Due to
the implementation of a variety of measures such as donor
selection, virus inactivation/removal, and the testing of
donations and of plasma pools, the risk of transmission of
blood-borne viruses, especially hepatitis B virus (HBV),
hepatitis C virus (HCV) and human immunodeficiency
virus (HIV), through plasma and plasma products has
been dramatically reduced in developed countries. In
2002, a guideline (the guideline of the technological
methods and validation of viral removal/inactivation of
blood products, No. 2002–160) was implemented in
China with the aim of improving the virus safety of
plasma derivatives. This guideline sets the Chinese stand-
ard for performing virus validation studies on medicinal
products derived from human plasma. The removal/
inactivation of viruses in these products requires the im-
plementation of production procedures including S/D
treatment, heat (pasteurization and dry heating), and
filtration [27]. For coagulation factor concentrates and
immunoglobulin, one or several combinational methods
should be used to inactivate/remove enveloped and non-
enveloped viruses, and albumin manufactured by cold
ethanol fractionation must be heat-treated (pasteurized)
in the final container. These methods are very effective
for the inactivation/removal of the aforementioned prin-
cipal viruses (HIV, HBV, and HCV); however, non-
enveloped viruses, such as B19V, cannot be efficiently
removed by these methods and therefore pose a residual
risk. This is because (1) plasma pools are prepared from
a large number of donations (more than 5000), and it is
likely that a high proportion of pools are contaminated
with B19V, potentially including some highly contami-
nated donations (up to 1014 geq/mL), and (2) B19V is ex-
tremely heat resistant and is small in size, which makes it
difficult to remove or inactivate by heat treatment or fil-
tration. B19V DNA contamination of plasma products
has been reported in several studies [28-32]; however, the
risk posed by Chinese plasma derivatives has not previ-
ously been addressed. In this study, coagulation factorives
B19V DNA (geq/mL)among positive lots
4 ≥ 103 ≥ 102 Log geq ± SEM
2 1 3.24 ± 0.44
2 0 4.92 ± 1.13
0 0 /
3 15 2.98 ± 0.65
9 4 3.76 ± 0.94
3 0 4.35 ± 1.26
4 4 3.54 ± 1.13
23 24
Table 5 B19V DNA and antibodies in plasma derivatives
with genome titers >104 geq/mL






Fibrinogen 1 6.64 × 104 Ne Ne
2 6.29 × 106 13 11.2
3 1.05 × 104 13 12
Factor VIII 1 1.22 × 105 Ne Ne
2 1.35 × 105 Ne 8.5
3 2.31 × 104 NA NA
4 3.08 × 104 NA NA
5 1.87 × 105 NA NA
6 1.17 × 105 Ne Ne
IVIG 1 1.19 × 104 144 Ne
2 1.09 × 104 72 Ne
3 1.22 × 104 138 Ne
4} 1.20 × 105 31 Ne
5} 1.55 × 107 7.5 11.5
6} 2.98 × 104 50 Ne
7} 1.24 × 106 74.9 Ne
8} 2.59 × 104 82 Ne
9} 4.82 × 104 38 Ne
10} 3.14 × 104 95 Ne
11} 3.37 × 105 110 100
PCC 1 3.47 × 104 Ne Ne
2 1.05 × 105 Ne 11.5
3 3.00 × 105 Ne 13
4 2.05 × 104 Ne 11.2
} Samples collected in the period 1993–1995; Ne, negative; NA, no data.
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gen and PCC were found to be highly contaminated with
B19V DNA at levels of 102 to 107 geq/mL. IVIG and
albumin were moderately contaminated with low levels
of B19V DNA.
Parvovirus B19V infection is relatively common world-
wide. In immunocompetent individuals, the infection
generally occurs without any serious consequences.
However, in specific groups, such as pregnant women,
patients with underlying hematological problems and
patients with immunodeficiency, B19V infections can re-
sult in serious complications[33-35]. It is estimated that
50% of all 15-year-olds in the western world have experi-
enced an infection [8]. However, in the elderly popula-
tion, higher percentages, as high as 80 or 100%, have
been observed [36].
A study in our laboratory on blood donors from many
Chinese regions reported the NAT testing of samples
from 3957 donors using an in-house developed Q-PCR
assay for the initial testing and a nested PCR assay for
confirmation. The study indicated a 0.58% genome DNAprevalence rate among the blood donor population [26],
but the study was not large enough to define range of
viral titers, as samples with very high titers are relatively
rare. In this study, we investigated B19V DNA contam-
ination in 142 plasma pools from two Chinese manufac-
turers. As indicated in Table 1, 77of 142 industrial
plasma pools (54.2%) were positive and 33 contained
B19V-DNA titers higher than 104 geq/mL. In the case of
manufacturer A, 30% of plasma pools were positive, but
in the case of manufacturer B, the majority (85.5%) were
positive. This may reflect a regional difference in B19V
infection prevalence. It is very interesting to found the
prevalence of B19V in the mini-pool (each contain 90
donations) from a total of 49,680 plasma donations from
manufacture A was 97%, much higher than that of other
pools collected from both companies during 2009–2011.
However, these individual plasmas were collected be-
tween August 2011 and March 2012 from company A
which located in the south of China. Winter and spring
are the epidemic periods of respiratory virus in this area.
This may reflect a temporal difference in B19V infection.
The quantity of B19V DNA varied from 102 to
3.07 × 108 geq/mL and approximately 43%(33 of 77 posi-
tive pools) of pools contained B19V DNA at titers higher
than 104 geq/mL, which was sufficiently large to con-
taminate the products produced from these plasma
pools. These data are consistent with previous reports
indicating that B19V-DNA is detectable in more than
60% of pools used for the production of plasma pro-
ducts, although usually at relatively low levels [28,37].
In this study, we identified one donation with a B19V
DNA titer of 1.09 × 1010 geq/mL, which was IgG/IgM
negative at the index time. Unexpectedly, B19V DNA
and IgG were positive, although the levels were lower
than that in a sample collected from the same individual
two weeks previously (Table 3). This is not consistent
with an acute B19V infection and probably indicates that
the donor had a persistent B19V infection, which is usu-
ally associated with anomalies in immune status or an
immune response that produces B19V antibodies that
are ineffective in neutralizing the virus, this result sup-
port the data of a previously study[25]. It is likely that,
in the days prior to the index time, B19V was reacti-
vated, which would have led to viral replication and a
rapid increase in viral load, and, thereby, neutralization
of the existing level of IgG. As indicated in Table 3,
during the following two months, B19V-DNA
decreased rapidly to 2.07 × 104 geq/mL, IgG gradually
increased to a plateau, and IgM decreased to a barely
detectable level. Other high titer donations are likely
to have contributed to a higher prevalence of B19V
DNA among plasma pools from manufacturer B. How-
ever, unfortunately, samples permitting further investi-
gation were unavailable.
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investigation was confined to the B19V genome content
of Chinese plasma pools and plasma derivatives, and the
infectivity of the virus in these samples was not deter-
mined. Nevertheless, although some inactivation/re-
moval methods have been implemented, these data
support the finding that B19V can be transmitted by
blood products [38-40] and that the B19V-DNA content
reflects, at least partly, contamination with the infectious
virus. Secondly, there are about 24 blood product manu-
facturers in China, and our investigation was restricted
to plasma pools from two of these. Thus, the data
obtained in this study does not reflect the nationwide
status of B19V contamination of blood products in
China and our results do not provide information about
regional and temporal differences in contamination
prevalence. Despite these limitations, our study repre-
sents the first investigation of B19V presence in Chinese
blood products.
Conclusion
B19V DNA was detected in Chinese plasma pools and
plasma derivatives with some high titer. Due to plasma
products are prepared from plasma pools and are admi-
nistered to large numbers of patients, including some
susceptible populations, such as pregnant women and
immunodeficient patients. We propose to introduce
B19V NAT into screening protocols for plasma dona-
tions and discard donation with high viramic concentra-
tion, with the aim of reducing the levels of parvovirus
B19V in pools destined for fractionation, has the poten-
tial to improve blood products safety in China.
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